Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study

被引:252
作者
Endo, Shigeatsu [1 ]
Suzuki, Yasushi [1 ]
Takahashi, Gaku [1 ]
Shozushima, Tatsuyori [1 ]
Ishikura, Hiroyasu [2 ]
Murai, Akira [2 ]
Nishida, Takeshi [2 ]
Irie, Yuhei [2 ]
Miura, Masanao [3 ]
Iguchi, Hironobu [3 ]
Fukui, Yasuo [4 ]
Tanaka, Kimiaki [4 ]
Nojima, Tsuyoshi [4 ]
Okamura, Yoshikazu [5 ]
机构
[1] Iwate Med Univ, Sch Med, Dept Crit Care Med, Morioka, Iwate 0208505, Japan
[2] Fukuoka Univ, Fac Med, Dept Emergency & Crit Care Med, Fukuoka 81401, Japan
[3] Kariya Toyota Gen Hosp, Anesthesiol Emergency & Crit Care Ctr, Kariya, Aichi, Japan
[4] Kochi Hlth Sci Ctr, Dept Surg Gastroenterol, Kochi, Japan
[5] Mitsubishi Chem Medience Corp, Yachiyo R&D Dept, Div Res & Dev, Tokyo, Japan
关键词
Presepsin; Soluble CD14-subtype; Procalcitonin; Sepsis; Infection; PROCALCITONIN; GUIDELINES;
D O I
10.1007/s10156-012-0435-2
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The clinical usefulness of presepsin for discriminating between bacterial and nonbacterial infections (including systemic inflammatory response syndrome) was studied and compared with procalcitonin (PCT) and interleukin-6 (IL-6) in a multicenter prospective study. Suspected sepsis patients (n = 207) were enrolled into the study. Presepsin levels in patients with systemic bacterial infection and localized bacterial infection were significantly higher than in those with nonbacterial infections. In addition, presepsin, PCT, and IL-6 levels in patients with bacterial infectious disease were significantly higher than in those with nonbacterial infectious disease (P < 0.0001, P < 0.0001, and P < 0.0001, respectively). The area under the receiver operating characteristic curve was 0.908 for presepsin, 0.905 for PCT, and 0.825 for IL-6 in patients with bacterial infectious disease and those with nonbacterial infectious disease. The cutoff value of presepsin for discrimination of bacterial and nonbacterial infectious diseases was determined to be 600 pg/ml, of which the clinical sensitivity and specificity were 87.8 % and 81.4 %, respectively. Presepsin levels did not differ significantly between patients with gram-positive and gram-negative bacterial infections. The sensitivity of blood culture was 35.4 %; that for presepsin was 91.9 %. Also there were no significant differences in presepsin levels between the blood culture-positive and -negative groups. Consequently, presepsin is useful for the diagnosis of sepsis, and it is superior to conventional markers and blood culture.
引用
收藏
页码:891 / 897
页数:7
相关论文
共 16 条
  • [1] Aikawa Naoki, 2005, Journal of Infection and Chemotherapy, V11, P152, DOI 10.1007/s10156-005-0388-9
  • [2] DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS
    BONE, RC
    BALK, RA
    CERRA, FB
    DELLINGER, RP
    FEIN, AM
    KNAUS, WA
    SCHEIN, RMH
    SIBBALD, WJ
    [J]. CHEST, 1992, 101 (06) : 1644 - 1655
  • [3] Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008
    Dellinger, R. Phillip
    Levy, Mitchell M.
    Carlet, Jean M.
    Bion, Julian
    Parker, Margaret M.
    Jaeschke, Roman
    Reinhart, Konrad
    Angus, Derek C.
    Brun-Buisson, Christian
    Beale, Richard
    Calandra, Thierty
    Dhainaut, Jean-Francois
    Gerlach, Herwig
    Harvey, Maurene
    Marini, John J.
    Marshall, John
    Ranieri, Marco
    Ramsay, Graham
    Sevransky, Jonathan
    Thompson, B. Taylor
    Townsend, Sean
    Vender, Jeffrey S.
    Zimmerman, Janice L.
    Vincent, Jean-Louis
    [J]. CRITICAL CARE MEDICINE, 2008, 36 (01) : 296 - 327
  • [4] Endo S, 2007, J JPN SOC SURG INFEC, V4, P112
  • [5] Endo Shigeatsu, 2008, Journal of Infection and Chemotherapy, V14, P244, DOI 10.1007/s10156-008-0608-1
  • [6] Furusako S, 2008, United States patent, Patent No. [US7465547 B2, 7465547]
  • [7] Furusako S, 2009, United States patent, Patent No. [US7608684 B2, 7608684, US7,608,684 B2]
  • [8] Kojika M., 2010, Med Postgraduates, V48, P46
  • [9] Evaluation of cardiac assays on a benchtop chemiluminescent enzyme immunoassay analyzer, PATHFAST
    Kurihara, Takashi
    Yanagida, Atsushi
    Yokoi, Hiroyuki
    Koyata, Atsushi
    Matsuya, Takeshi
    Ogawa, Junichi
    Okamura, Yoshikazu
    Miyamoto, Daishi
    [J]. ANALYTICAL BIOCHEMISTRY, 2008, 375 (01) : 144 - 146
  • [10] Pathobiochemistry and clinical use of procalcitonin
    Meisner, M
    [J]. CLINICA CHIMICA ACTA, 2002, 323 (1-2) : 17 - 29